Shots: The approval is based on REACH‑2 study (NCT02435433) results assessing Cyramza (ramucirumab) + BSC vs PBO + BSC in 292 advanced HCC patients in the ratio (2:1) with alpha-fetoprotein […]readmore
Tags : Second line